Autoantibodies to Cytosolic 5′-Nucleotidase 1A in Primary Sjogren's Syndrome and Systemic Lupus Erythematosus

被引:27
|
作者
Rietveld, Anke [1 ]
van den Hoogen, Luuk L. [2 ]
Bizzaro, Nicola [3 ]
Blokland, Sofie L. M.
Daehnrich, Cornelia
Gottenberg, Jacques-Eric [5 ]
Houen, Gunnar [6 ]
Johannsen, Nora [4 ]
Mandl, Thomas
Meyer, Alain
Nielsen, Christoffer T. [9 ]
Olsson, Peter [7 ,8 ]
van Roon, Joel
Schlumberger, Wolfgang
van Engelen, Baziel G. M.
Saris, Christiaan G. J.
Pruijn, Ger J. M. [10 ]
机构
[1] Radboud Univ Nijmegen Med Ctr, Donders Inst Brain, Dept Neurol Ctr Neuroscience, Cognit & Behaviour, Nijmegen, Netherlands
[2] Univ Utrecht, Dept Rheumatol & Clin Immunol Univ Med Ctr Utrech, Lab Translat Immunol, Utrecht, Utrecht, Netherlands
[3] Laboratorio Patologia Clin Ospedaie San Antonio A, Tomezzo, Italy
[4] Inst Expt Immunol Euroimmun AG Lubeck Germany, Lubeck, Germany
[5] Univ Strasbourg, Ctr reference Malad auto immunes rares & Federat, Serv physiol & dexplorat fonctionnelles, Serv Rhumatol, Strasbourg, France
[6] Statens Serum Inst, Dept Autoimmunol & Biomarkers, Copenhagen, Denmark
[7] Lund Univ, Dept Clin Sci Malmo, Malmo, Sweden
[8] Skane Univ Hosp, Dept Rheumatol, Malmo, Sweden
[9] Ctr Rheumatol & Spine Dis Rigshospitalet Copenhag, Copenhagen Lupus & Vasculitis Clin, Copenhagen, Denmark
[10] Radboud Univ Nijmegen, Dept Biomol Chem Radboud Inst Pviolecular Life Sc, Nijmegen, Netherlands
来源
FRONTIERS IN IMMUNOLOGY | 2018年 / 9卷
关键词
Cytosolic 5 '-nucleotidase 1A; anti-cN-1A; NT5CIA; autoantibodies; inclusion body myositis; Sjogren's syndrome; systemic lupus erythematosus; INCLUSION-BODY MYOSITIS; DIAGNOSTIC UTILITY; CLASSIFICATION; ANTIBODIES; CRITERIA; NT5C1A; ELISA;
D O I
10.3389/fimmu.2018.01200
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Autoantibodies to cytosolic 5'-nucleotidase 1A (cN-1A; NT5C1A) have a high specificity when differentiating sporadic inclusion body myositis from polymyositis and dermatomyositis. In primary Sjogren's syndrome (pSS) and systemic lupus erythematosus (SLE) anti-cN -1A autoantibodies can be detected as well. However, various frequencies of anti-cN -1A reactivity have been reported in SLE and pSS, which may at least in part be explained by the different assays used. Here, we determined the occurrence of anti-cN-1A reactivity in a large number of patients with pSS and SLE using one standardized ELISA. Methods: Sera from pSS (n = 193) and SLE patients (n = 252) were collected in five European centers. Anti-cN-1A, anti-Ro52, anti-nucleosome, and anti-dsDNA reactivities were tested by ELISA (Euroimmun AG) in a single laboratory. Correlations of anti-cN-1A reactivity with demographic data and clinical data (duration of disease at the moment of serum sampling, autoimmune comorbidity and presence of muscular symptoms) were analyzed using SPSS software. Results: Anti-cN-1A autoantibodies were found on average in 12% of pSS patients, with varying frequencies among the different cohorts (range: 7-19%). In SLE patients, the anti-cN-1A positivity on average was 10% (range: 6-21%). No relationship was found between anti-cN-1A reactivity and the presence or absence of anti-Ro52, antinucleosome, and anti-dsDNA reactivity in both pSS and SLE. No relationship between anti-cN -1A reactivity and duration of disease at the moment of serum sampling and the duration of serum storage was observed. The frequency of muscular symptoms or viral infections did not differ between anti-cN-1A-positive and- negative patients. In both disease groups anti-cN-1A-positive patients suffered more often from other autoimmune diseases than the anti-cN-1A-negative patients (15 versus 5% (p = 0.05) in pSS and 50 versus 30% (p = 0.02) in SLE). Conclusion: Our results confirm the relatively frequent occurrence of anti-cN-1A in pSS and SLE patients and the variation in anti-cN-1A reactivity between independent groups of these patients. The explanation for this variation remains elusive. The correlation between anti-cN-1A reactivity and polyautoimmunity should be evaluated in future studies. We conclude that anti-cN-1A should be classified as a myositis-associated-, not as a myositis-specific-autoantibody based on its frequent presence in SLE and pSS.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Shrinking lung syndrome in systemic lupus erythematosus and Sjogren's syndrome
    Singh, R
    Huang, WQ
    Menon, Y
    Espinoza, LR
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2002, 8 (06) : 340 - 345
  • [22] Nephrocalcinosis in a patient with Sjogren's syndrome/systemic lupus erythematosus
    Damasceno Zanuto, Amanda Carolina
    Bueno, Tatiara
    Alvares Delfino, Vinicius Daher
    Mocelin, Altair Jacob
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2012, 58 (03): : 279 - 280
  • [23] Myositis in Systemic Sclerosis, Lupus Erythematosus and Sjogren's Syndrome
    Keck, A. D.
    Jaeger, V. K.
    Walker, U. A.
    AKTUELLE RHEUMATOLOGIE, 2017, 42 (04) : 310 - 315
  • [24] Neuroendocrine changes in systemic lupus erythematosus and Sjogren's syndrome
    Fox, RA
    Moore, PM
    Isenberg, DA
    BAILLIERES CLINICAL RHEUMATOLOGY, 1996, 10 (02): : 333 - 347
  • [25] Sjogren's syndrome and systemic lupus erythematosus: links and risks
    Pasoto, Sandra Gofinet
    de Oliveira Martins, Victor Adriano
    Bonfa, Eloisa
    OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2019, 11 : 33 - 45
  • [26] Psychiatric manifestations of lupus erythematosus systemic and Sjogren's syndrome
    Ampélas, JF
    Wattiaux, MJ
    Van Amerongen, AP
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2001, 27 (06): : 588 - 599
  • [27] Cytokine polymorphisms in systemic lupus erythematosus and Sjogren's syndrome
    Magnusson, V
    Nakken, B
    Bolstad, AI
    Alarcón-Riquelme, ME
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2001, 54 (1-2) : 55 - 61
  • [28] Pulmonary manifestations of systemic lupus erythematosus and Sjogren's syndrome
    Velazquez, Marco Lopez
    Highland, Kristin B.
    CURRENT OPINION IN RHEUMATOLOGY, 2018, 30 (05) : 449 - 464
  • [29] Genetics of systemic lupus erythematosus and Sjogren's syndrome: an update
    Teruel, Maria
    Alarcon-Riquelme, Marta E.
    CURRENT OPINION IN RHEUMATOLOGY, 2016, 28 (05) : 506 - 514
  • [30] Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis
    Narain, Sonali
    Berman, Nicola
    Furie, Richard
    CURRENT OPINION IN RHEUMATOLOGY, 2020, 32 (06) : 609 - 616